Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Advanced Solid Tumours
- Main trialPhase 1
- “This is a first-in-human, multicentre, Phase 1, open-label study designed to evaluate the safety and tolerability of DAX-044 as monotherapy, and to determine its maximum tolerated dose, in adults with advanced solid tumours.”In the company’s words, NCT07950930 on ClinicalTrials.gov
Other drugs for Advanced Solid Tumours
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- 10 Aug 2030Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 20 NovNew trial: none to Phase 1 · ClinicalTrials.gov NCT07950930
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 10 Aug 2030 | DAX-044 in Adults With Advanced Solid Tumours: a First-in-human Study of Safety, Dose and Early Anti-cancer Activity. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026